A Dose-finding Study of ASP4070

Summary

The objective of this study was to evaluate the efficacy, safety, and dose-response of ASP4070 vaccinated in patients with cedar pollinosis.

Timeline

Start

2017-04-13

Primary completion

2018-01-26

Completion

2018-10-27

Outcome

Missed primary endpoint

registry analysis (superiority test); ASP4070 4 mg vs Placebo; p = 0.777; Adjusted mean difference 0.09 (95% CI -0.52 to 0.69); Mixed model for repeated measures (MMRM) NCT03101267 ↗

registry analysis (superiority test); ASP4070 1 mg vs Placebo; p = 0.983; Adjusted mean difference -0.01 (95% CI -0.61 to 0.59); MMRM NCT03101267 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ASP4070	Vaccine	1 mg	Other
Subject	ASP4070	Vaccine	4 mg	Other

Indications